You are here

  • Home
  • Archive
  • Volume 8, Issue 1
  • Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab

Article metrics

Article menu

Download PDFPDF

XML
Case report
Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab

 

Online download statistics by month:

Online download statistics by month: March 2020 to July 2025

AbstractFullPdf
Mar 2020364364116
Apr 202025625660
May 2020727218
Jun 2020525216
Jul 2020414125
Aug 202023239
Sep 2020505036
Oct 2020404019
Nov 2020383819
Dec 202030309
Jan 2021383817
Feb 2021353520
Mar 2021595921
Apr 2021242418
May 2021262614
Jun 2021232315
Jul 2021656510
Aug 2021363612
Sep 202122226
Oct 2021484823
Nov 2021252518
Dec 2021272710
Jan 202219205
Feb 202210108
Mar 202225274
Apr 2022283015
May 2022262713
Jun 202234346
Jul 202231329
Aug 202223237
Sep 2022303040
Oct 202232327
Nov 2022232521
Dec 202228287
Jan 202314143
Feb 2023545511
Mar 2023202111
Apr 20236610
May 202319199
Jun 2023992
Jul 202312139
Aug 202321217
Sep 202324241
Oct 2023171710
Nov 202327277
Dec 202326267
Jan 202417186
Feb 2024181810
Mar 2024171734
Apr 2024323222
May 2024232525
Jun 2024323117
Jul 2024464716
Aug 2024191711
Sep 2024151510
Oct 2024161615
Nov 2024272813
Dec 2024131513
Jan 2025323254
Feb 2025767623
Mar 2025242432
Apr 2025353515
May 2025262624
Jun 2025202017
Jul 2025110
Total244124571097